CV Sciences (OTCQB:CVSI) will meet with the FDA to discuss its initial drug candidate (CVSI-007), a chewing gum that combines CBD and nicotine, to treat smokeless tobacco addiction.
As quoted in the press release:
According to the CDC, smokeless tobacco has been associated to numerous health problems including causing cancer of the mouth, esophagus, and pancreas. It can lead to nicotine addiction, can increase risks during pregnancy, and may increase the risk for death from heart disease and stroke.
CV Sciences’ President and CEO Michael Mona, Jr. commented, “Smokeless tobacco continues to be a major health hazard and epidemic as we have been reporting on the industry’s unmet needs in treating this addiction, between Major League Baseball’s (MLB) decision to ban smokeless chewing tobacco for new players and most recently, the U.S. Department of Defense’s (DoD’s) campaign to provide assistance to military personnel looking to quit the use of smokeless tobacco. This further demonstrates a mainstream push towards treating and reducing smokeless tobacco addiction, an unserved medical indication with no FDA-approved product. We believe our drug candidate can have a significant positive impact on patients seeking treatment. We look forward to our meeting with the FDA, as it will be essential to the design of our clinical development program and the filing of our Investigational New Drug (IND) application.”